Related Experiment Videos
Glitazones: clinical effects and molecular mechanisms
Michael Stumvoll1, Hans-Ulrich Häring
1Medizinische Klinik, Abteilung für Endokrinologie, Stoffwechsel und Pathobiochemie, Eberhard-Karls-Universität, Tübingen, Germany. michael.stumvoll@med.uni-tuebingen.de
Annals of Medicine
|August 14, 2002
Summary
Thiazolidinediones like rosiglitazone improve type 2 diabetes by reducing insulin resistance. These drugs target the PPARgamma receptor, offering a new treatment concept with potential for diabetes prevention, though long-term data are needed.
Area of Science:
- Endocrinology and Metabolism
- Pharmacology
Background:
- Type 2 diabetes is a growing global health concern characterized by insulin resistance.
- Thiazolidinediones represent a novel therapeutic class for managing type 2 diabetes.
Purpose of the Study:
- To evaluate the efficacy and mechanism of action of thiazolidinediones (rosiglitazone and pioglitazone) in treating type 2 diabetes.
- To explore the potential of thiazolidinediones in non-diabetic conditions associated with insulin resistance.
Main Methods:
- The study reviews the mechanism of action of thiazolidinediones, focusing on their interaction with peroxisome proliferator-activated receptor gamma (PPARγ).
- Analysis of clinical data on the effects of thiazolidinediones on blood glucose and HbA1c levels.
- Examination of thiazolidinediones' impact on insulin sensitivity mediators in adipose tissue.
Main Results:
- Thiazolidinediones, as monotherapy, improve fasting blood glucose by ~40 mg/dl and HbA1c by ~1%.
- Their efficacy is additive when used in combination with other anti-diabetic agents.
- These drugs reduce insulin resistance by modulating gene expression via PPARγ, primarily in adipose tissue, leading to improved insulin sensitivity in muscle and liver.
Conclusions:
- Thiazolidinediones offer a novel approach to treating insulin resistance and type 2 diabetes.
- Potential for use in preventing type 2 diabetes exists, but long-term human data are essential for a comprehensive risk-benefit assessment.
- While hepatotoxicity concerns from troglitazone are unlikely with rosiglitazone and pioglitazone due to metabolic differences, fluid retention remains a notable side effect.